EAPH
Dr. Bagi and BMV estimate the regulatory process to require six to seven months after filing until a marketing approval is obtained. In parallel with the regulatory filing, Easton Pharmaceuticals, through the efforts and relationships of Dr. Bagi, has begun talks with several large companies with a presence in sales and marketing in the women's health, sexual arousal disorder and the sexual wellness markets. Easton believes, barring any long financing delays, that these regulatory and commercial alliance initiatives running in parallel will enable a timely, successful launch of Viorra in Mexico in 2012.
"We are very pleased with the appointment of Dr. Daniel Bagi as a chief consultant who with his many contacts in Mexico, knowledge and belief in our Viorra product, and well established credentials will prove to be a huge asset to the company," stated John Easton, Easton Pharmaceuticals' CEO and Chairman of the Board.
Viorra is an over-the-counter aid for the treatment to restore and improve vaginal elasticity and moisture which has shown to give a positive effect on women's sexual desire and arousal, helping to alleviate FSAD (Female Sexual Arousal Disorder). Viorra is a topical, daily-use product formulated with ingredients classified by the FDA as Generally Recognized as Safe.
News 
Market Data 
Discover 
